We are live on ! Find out more
CIP

Convergence Investment Partners Portfolio holdings

AUM $1.06B
1-Year Est. Return 87.75%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+87.75%
3 Year Est. Return
+284.25%
5 Year Est. Return
+379.02%
10 Year Est. Return
+1,390.46%
AUM
$706M
AUM Growth
+$22.2M
Cap. Flow
-$18.7M
Cap. Flow %
-2.65%
Top 10 Hldgs %
13.02%
Holding
439
New
101
Increased
102
Reduced
110
Closed
126

Top Sells

Rank Stock Value
1
EVR icon
Evercore
EVR
+$4.64M
2
DF
Dean Foods Company
DF
+$4.6M
3
AVA icon
Avista
AVA
+$4.2M
4
SAIC icon
Saic
SAIC
+$4.18M
5
PFE icon
Pfizer
PFE
+$4.06M

Sector Composition

Rank Sector Weight
1 Financials 16.13%
2 Industrials 13.97%
3 Healthcare 13.19%
4 Technology 12.92%
5 Consumer Discretionary 10.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LEA icon
126
Lear
LEA
$6.21B
$2.14M 0.3%
12,373
+54
+0.4% +$8.17K
VRTX icon
127
Vertex Pharmaceuticals
VRTX
$121B
$2.12M 0.3%
13,956
+2,857
+26% +$430K
CC icon
128
Chemours
CC
$2.7B
$2.11M 0.3%
41,711
+285
+0.7% +$13.4K
MMS icon
129
Maximus
MMS
$3.33B
$2.1M 0.3%
32,621
+6,990
+27% +$428K
CA
130
DELISTED
CA, Inc.
CA
$2.1M 0.3%
62,873
-15
-0% -$496
GL icon
131
Globe Life
GL
$14.3B
$2.09M 0.3%
+26,066
New +$2.03M
FCX icon
132
Freeport-McMoran
FCX
$96.7B
$2.08M 0.3%
148,393
+31,278
+27% +$439K
EWBC icon
133
East-West Bancorp
EWBC
$18.3B
$2.08M 0.29%
34,707
-35,443
-51% -$2.01M
EBS icon
134
Emergent Biosolutions
EBS
$391M
$2.07M 0.29%
+51,066
New +$1.85M
RF icon
135
Regions Financial
RF
$27.3B
$2.05M 0.29%
134,330
-30,643
-19% -$441K
ETN icon
136
Eaton
ETN
$173B
$2.02M 0.29%
26,333
-139
-0.5% -$10.5K
RDN icon
137
Radian Group
RDN
$5.27B
$2.02M 0.29%
+107,978
New +$1.87M
LVS icon
138
Las Vegas Sands
LVS
$29.8B
$1.97M 0.28%
30,629
+3,271
+12% +$203K
ANDV
139
DELISTED
Andeavor
ANDV
$1.95M 0.28%
18,871
-28,535
-60% -$2.81M
DVA icon
140
DaVita
DVA
$14.6B
$1.91M 0.27%
32,201
+5,382
+20% +$324K
FR icon
141
First Industrial Realty Trust
FR
$8.5B
$1.89M 0.27%
+62,759
New +$1.9M
BLDR icon
142
Builders FirstSource
BLDR
$8.11B
$1.88M 0.27%
+104,443
New +$1.68M
SUPN icon
143
Supernus Pharmaceuticals
SUPN
$2.51B
$1.88M 0.27%
46,960
+1,519
+3% +$65.7K
RCL icon
144
Royal Caribbean
RCL
$87.1B
$1.88M 0.27%
15,814
+1,591
+11% +$186K
BPOP icon
145
Popular Inc
BPOP
$11.2B
$1.86M 0.26%
+51,759
New +$2.09M
LGND icon
146
Ligand Pharmaceuticals
LGND
$6.03B
$1.84M 0.26%
+21,644
New +$1.71M
MET icon
147
MetLife
MET
$61.9B
$1.83M 0.26%
35,313
-6,576
-16% -$320K
DLB icon
148
Dolby
DLB
$5.73B
$1.82M 0.26%
+31,703
New +$1.66M
AMP icon
149
Ameriprise Financial
AMP
$48.9B
$1.8M 0.26%
12,133
-142
-1% -$19.8K
CMI icon
150
Cummins
CMI
$87.8B
$1.77M 0.25%
10,543
-89
-0.8% -$14.4K

Similar funds

Convergence Investment Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Convergence Investment Partners held 439 positions worth $706M, up 3.2% from $684M the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Convergence Investment Partners's Q3 2017 filing shows 101 new, 102 increased, 110 reduced and 126 closed positions. Its largest new stake was Celgene Corp: 35,534 shares worth $5.18M. The largest sale was Evercore, an estimated $4.64M.

By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 18% a quarter earlier, followed by Industrials and Healthcare.

  • Convergence Investment Partners's largest Q3 2017 buy was Celgene Corp: 35,534 shares worth $5.18M.
  • Convergence Investment Partners added most to Pattern Energy Group Inc. Class A in Q3 2017, an estimated $4.8M increase.
  • Convergence Investment Partners's biggest Q3 2017 reduction was Saic, cutting an estimated $4.18M.
  • Convergence Investment Partners fully exited Evercore in Q3 2017, selling an estimated $4.64M.
  • Convergence Investment Partners's ten largest holdings make up 13% of its $706M portfolio in Q3 2017.
  • Convergence Investment Partners opened 101 new positions and closed 126 in Q3 2017.
  • Convergence Investment Partners's portfolio value rose 3.2% quarter-over-quarter to $706M.

Based on Convergence Investment Partners's 13F filing for Q3 2017, filed 13 Nov 2017.